Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
針對已有腎結石或痛風患者的反覆腎結石，鈉-葡萄糖共轉運蛋白-2 抑制劑的比較效果：目標試驗模擬研究。
BMJ 2024-10-30
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
腎素葡萄糖共同轉運蛋白2抑制劑對於痛風復發和痛風原發性急診就診及住院的比較效果：一項一般人口群體的共同研究。
Ann Intern Med 2024-04-02
Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.
痛風發作及鈉葡萄糖共轉運輸蛋白2抑制劑治療對痛風和2型糖尿病患者的死亡率影響。
JAMA Netw Open 2023-10-02
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
第二型糖尿病患者中鈉葡萄糖共同轉運蛋白2抑制劑與腎結石風險。
JAMA Intern Med 2024-03-05
Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?
SGLT2抑制劑在腎結石治療中的應用：我們應該對患有腎結石疾病的患者使用「gliflozin」嗎？
J Bras Nefrol 2024-03-23
Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
二型糖尿病患者在接受二甲双胍治療時，使用鈉葡萄糖共同轉運蛋白2抑制劑與磺醯脲類藥物預防痛風的比較。
JAMA Intern Med 2024-04-18
SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum.
SGLT2 抑制劑，但非 GLP-1 受體激動劑，降低2型糖尿病患者痛風的發生率。
Clin Ther 2024-07-27
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14